Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug ST316 shrink Hard-to-Treat tumors?

NCT ID NCT05848739

Ongoing Disease control Sponsor: Sapience Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The goal is to see if ST316 is safe and whether it can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called ST316, given alone or with chemotherapy (FOLFIRI, fruquintinib, or Lonsurf) plus bevacizumab
What this could lead to
If it works, this could point toward a new treatment option for advanced colon cancer and other solid tumors that are hard to treat.
What could go wrong
This is an early-phase trial, so the drug may not be effective or could cause unexpected side effects. Results are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma colon carcinoma colonic neoplasm colorectal cancer hepatocellular carcinoma melanoma metastatic malignant neoplasm in the colon non-small cell lung carcinoma ovarian cancer sarcoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER METASTATIC COLON CANCER

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Duke Universtiy

    Durham, North Carolina, 27708, United States

  • Fred Hutch Cancer Center

    Seattle, Washington, 98109, United States

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • Ochsner Clinic Foundation

    New Orleans, Louisiana, 70123, United States

  • START Midwest

    Grand Rapids, Michigan, 49503, United States

  • Sanford Cancer Center

    Sioux Falls, South Dakota, 57104, United States

  • Sarah Cannon Research Institute - CO

    Denver, Colorado, 80218, United States

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Alabama

    Birmingham, Alabama, 35294, United States

  • Westchester Medical Center

    Valhalla, New York, 10595, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.